evipedia.ai
← Back

Zeolite for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: Clinoptilolite, Zeolite Clinoptilolite, Natural Zeolite, Micronized Zeolite, Tribomechanically Activated Zeolite, TMAZ, PMA-Zeolite, Purified Clinoptilolite Tuff, G-PUR, Megamin

Motivation

Zeolite is a family of volcanic minerals whose crystals form a rigid, sponge-like lattice riddled with channels about the width of a few molecules. Those channels carry a mild negative charge, so the mineral can trap and swap small charged particles as it travels through the digestive tract. The variety sold for oral use in people is clinoptilolite, ground to a powder and promoted mainly as a binder of metals and other unwanted material in the gut.

Rock rich in this mineral has been added to livestock feed and used to clean water for decades, and human use followed that industrial track rather than a laboratory discovery. Small clinical studies have since reported effects on bowel symptoms, blood fats, and how the body handles metals. Critics counter that the mineral simply passes through unchanged and that commercial powders vary widely in purity.

This review examines what controlled human studies, laboratory work, and regulatory safety assessments establish about oral zeolite, where the evidence remains thin or contested, and what the trade-offs look like for adults pursuing long-term health and longevity.

Benefits - Risks - Protocol - Conclusion

High-level overviews of zeolite in medicine, selected for depth on the mineral itself rather than on a single indication.

Only four items are listed. Of the priority platforms, none of Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser or Lifespan.io has published content on zeolite; only Life Extension covers it, within its heavy-metal protocol. Beyond that, the non-excluded literature is thin, and the list has not been padded with marginally relevant material.

Grokipedia

  • Zeolite

    Covers framework chemistry, ion exchange and adsorption, natural versus synthetic species, and industrial scale. Useful for grounding the mineral’s structural claims before assessing the health literature built on them.

Examine

No Examine article exists for zeolite. Searches of examine.com for both “zeolite” and “clinoptilolite” returned no results in any database, supplement page or article.

ConsumerLab

Systematic Reviews

Systematic reviews and meta-analyses that bear on zeolite, ordered from the most directly relevant to the mineral as an ingested agent.

The trade-off at the centre of this review is not evenly represented. Reviews exist for the claimed binding and gastrointestinal effects, but no systematic review or meta-analysis covers the principal risk — depletion of essential minerals or exposure to contaminants in commercial powders — and none covers oral zeolite in humans at all; that side is unrepresented in the systematic-review literature.

Mechanism of Action

Clinoptilolite is a hydrated aluminosilicate: a crystalline lattice of silicon-oxygen and aluminium-oxygen tetrahedra whose channels measure roughly 0.3–1 nanometre. Substituting aluminium for silicon leaves the framework negatively charged, balanced by loosely held sodium, potassium and calcium ions. Those ions can be swapped for others encountered in the gut, which is the basis of every proposed effect.

Three mechanisms are advanced. First, cation exchange: heavier metal ions such as lead and cadmium bind more tightly than the resident ions and are carried out in stool, reducing how much crosses the intestinal wall. Second, physical adsorption of neutral small molecules — ammonia, ethanol, bile acids, mycotoxins — into the pores. Third, surface dissolution releasing small amounts of soluble silica, proposed as a systemic signal for bone and connective tissue.

A competing explanation holds that the mineral is essentially inert ballast: it is not absorbed, so any systemic change must be secondary to what it removes, and effects on bone or immune markers are better explained by placebo response, regression to the mean (extreme starting values drifting back toward average on retesting), or the particle simply irritating and then adapting the gut lining.

Pharmacologically the material has no systemic profile. It is not absorbed, not distributed to tissues, and not metabolised by liver enzymes; there is no meaningful half-life, only gastrointestinal transit of roughly one to two days. Acidic stomach conditions can partially strip aluminium from the framework, a process called dealumination.

Historical Context & Evolution

Zeolites were named in 1756 by the mineralogist Axel Fredrik Cronstedt, from Greek words for “boiling stone”, after he watched water steam out of the heated rock. For two centuries the interest was purely industrial: gas separation, water softening, detergent builders and petroleum cracking catalysts.

Agricultural use came next. Clinoptilolite-rich tuff (compacted volcanic ash rock) was added to livestock feed in Japan and the Balkans from the 1960s as an anticaking agent and ammonia binder, and after the 1986 Chernobyl accident, zeolite was fed to animals and added to foodstuffs to bind radioactive caesium and strontium. That agricultural track, not a pharmaceutical programme, is what carried the mineral into human use.

The pivotal medical claim came from a Croatian group in 2001, which reported that finely ground clinoptilolite fed to tumour-bearing mice and to dogs with spontaneous tumours improved overall health, prolonged lifespan and shrank tumours, alongside cell-culture work showing blocked growth signalling (Pavelić et al., 2001). No human series accompanied it, yet consumer products followed quickly. Regulators pushed back: the United States Food and Drug Administration issued warning letters in 2007 to a zeolite marketer for promoting products as cancer, diarrhoea and hangover treatments.

Opinion has not settled. The mineral gained European feed authorisation and, later, medical-device status for gut applications, while independent reviewers continued to call the human evidence scanty (Laurino & Palmieri, 2015). Both the original findings and the regulatory objections remain on the record, with replication still the open question.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every human outcome in this literature — blood lead, lipid fractions, fracture incidence, chemotherapy tolerance — rests on a single clinical trial, and no finding has been reproduced in a second controlled human study.

Medium 🟩 🟩

Reduced Absorption of Ingested Lead

The mineral binds lead ions in the gut so that less crosses into the bloodstream. In a randomised, placebo-controlled, double-blind trial in 42 healthy adults, purified clinoptilolite tuff taken together with a stable lead tracer cut the tracer’s appearance in blood dramatically, with a parallel fall in urinary excretion confirming reduced uptake rather than faster clearance (Samekova et al., 2021). This tests concurrent binding of an ingested dose, not removal of lead already stored in bone. The trial was run with the manufacturer, Glock Health, Science and Research.

Magnitude: Peak tracer enrichment fell from 0.505% of total blood lead on placebo to 0.073% at 2.0 g and 0.057% at 4.0 g; cumulative exposure fell from 86.5 to 11.9 and 8.5 percent-hours, roughly a 90% reduction.

Improved Tolerance of Oxaliplatin-Based Chemotherapy

Patients on oxaliplatin, a platinum chemotherapy drug, frequently develop chemotherapy-induced peripheral neuropathy (CIPN, nerve damage in hands and feet). In a randomised, double-blind, placebo-controlled trial of 120 patients with mostly colorectal cancer, PMA-zeolite did not significantly reduce neuropathy overall but did in men, and treated patients completed more chemotherapy cycles. Blood-count toxicity trended lower. The manufacturer Panaceo International co-authored and funded the trial (Vitale et al., 2020).

Magnitude: Neuropathy occurred in 64.3% on zeolite versus 70.6% on placebo overall (not significant), but was significantly lower in men (p = 0.047; a p value below 0.05 means a result that big would be unlikely to arise by chance alone); more chemotherapy cycles were completed (p = 0.03).

Low 🟩

Relief of Diarrhoea-Predominant Irritable Bowel Syndrome Symptoms ⚠️ Conflicted

A double-blind trial in 30 patients with diarrhoea-predominant irritable bowel syndrome missed its primary endpoint, 21% versus 25% relief, though pain and stool frequency improved (Anderle et al., 2022). A manufacturer-run uncontrolled study of 204 patients reported gains (Mosgoeller et al., 2024). Net reading: the only controlled trial was negative.

Magnitude: Median diarrhoea days per week fell by 2.4 on zeolite versus 0.3 on placebo; primary relief endpoint 21% versus 25%.

Improved Blood Lipid Profile

In an open-label, uncontrolled dose-ranging study of 41 adults with elevated blood fats, eight weeks of activated clinoptilolite lowered all lipid fractions, reversing six weeks after stopping — consistent with bile-acid binding (Cutovic et al., 2017). There was no control group and a single centre.

Magnitude: Total cholesterol and low-density lipoprotein cholesterol fell 19–23% at eight weeks in the finest-grind 6 g/day group; 20–25% across all groups combined.

Lower Blood Alcohol Concentration After Drinking ⭕️ Not Central to Health & Longevity

Clinoptilolite adsorbs ethanol in the stomach before it is absorbed. In an uncontrolled 12-person crossover pilot, 5 g taken with alcohol lowered measured blood alcohol; 2.5 g did not (Federico et al., 2015). This bears on acute intoxication and hangover, not on long-term health outcomes.

Magnitude: Blood ethanol fell 43%, 35%, 41% and 34% at 30, 60, 90 and 120 minutes with 5 g; no significant change at 2.5 g.

Reduced Fracture Incidence in Osteoporosis ⚠️ Conflicted

In a five-year double-blind trial in 100 patients with osteoporosis, manufacturer-run, PMA-zeolite was associated with fewer fractures and formation-favouring bone markers, yet bone mineral density matched placebo; the fracture comparison used pre-trial history (Kraljević Pavelić et al., 2022). Net reading: a bone-quality effect is possible but undemonstrated against control.

Magnitude: Fracture risk fell significantly versus each patient’s pre-study period (p = 0.002), and bone mineral density was unchanged versus placebo; the report gives no fracture rate, risk ratio or other outcome figure.

Speculative 🟨

Improved Intestinal Barrier Integrity

A randomised placebo-controlled trial in 52 endurance-trained adults found 12 weeks of zeolite lowered stool zonulin, a marker of gut tight-junction leakiness (Lamprecht et al., 2015). Zonulin is not validated against clinical outcomes.

Immune Cell Modulation

An open, manufacturer-run study in 61 patients with immunodeficiency reported shifts in lymphocyte subsets after six to eight weeks (Ivkovic et al., 2004). Cell counts are unvalidated surrogates for immune competence.

Antioxidant and Anti-Inflammatory Activity

A randomised trial in 85 smokers matched vitamin E on antioxidant markers (Atitlán-Gil et al., 2017); cell and rodent work adds dampened inflammatory signalling via endotoxin adsorption (Kavaliauskas et al., 2026). These markers are unvalidated.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic variant has been studied for zeolite. Variants in ALAD (delta-aminolevulinic acid dehydratase, an enzyme in red-cell pigment synthesis that binds lead) and HFE (the gene controlling iron absorption) alter metal handling and plausibly shift how much binding matters.

  • Baseline biomarker levels: Benefit from metal binding scales with ongoing exposure. Adults with low baseline blood lead, cadmium or arsenic have little to gain, whereas measurable baseline burden or continuing dietary and occupational exposure is where the binding effect has room to act.

  • Sex-based differences: Both quantified effects were larger in men. Neuropathy reduction during chemotherapy reached significance only in the male subgroup, and blood alcohol reduction was more pronounced in men, plausibly reflecting body-water and gastric alcohol-metabolism differences rather than the mineral itself.

  • Pre-existing health conditions: Gastrointestinal effects were largest in diarrhoea-predominant bowel syndrome and least apparent in constipation-predominant patients. Reduced stomach acid, common with acid-suppressing therapy, lowers ion exchange and would be expected to blunt binding.

  • Age-related considerations: Older adults carry higher lifetime bone lead stores that can be mobilised during bone remodelling, and produce less stomach acid. Both shift the balance: potentially more to bind, but less efficient binding, and the osteoporosis data come from this age group.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one controlled human trial, the available human safety signals being mineral and metal measurements in single supplementation cohorts, with the remainder laboratory adsorption data rather than recorded human adverse events.

Medium 🟥 🟥

Depletion of Essential Minerals

Ion exchange is not selective, so nutritionally essential cations can be carried out alongside toxic ones. Pooled monitoring across three clinical trials of PMA-zeolite found copper falling in patients with osteoporosis, and sodium and calcium dropping below reference values in that group; copper normalised with continued long-term use (Kraljević Pavelić et al., 2022). The report comes from the manufacturer-linked research group and recommends checking copper, calcium and sodium after a year of use.

Magnitude: Direction is downward for copper, sodium and calcium, and it emerged specifically in osteoporotic patients on multi-year supplementation; the report gives no effect size for the change.

Transient Increase in Circulating Lead

The same monitoring found blood lead rising during short-term and long-term supplementation before falling again with continued use, attributed to lead being released from bone during remodelling rather than to contamination of the product (Kraljević Pavelić et al., 2022). Rodent work shows the same pattern: tissue metal stores fall while serum levels transiently rise (Dolanc et al., 2023). Mobilised lead is biologically active while in circulation.

Magnitude: Direction is a rise in blood lead during the first months of supplementation, reversing with continued intake; no numerical effect size is reported in the source.

Low 🟥

Gastrointestinal Symptoms

Constipation, bloating, abdominal discomfort and nausea are the usual complaints with any insoluble binder. Zeolite trials record them as mild and short-lived, with no product-related serious adverse events in the 12-week bowel trial (Anderle et al., 2022). Trial populations were small, screened and short-term.

Magnitude: Not quantified in available studies. No trial has published an adverse-event incidence table for gastrointestinal complaints, and the cohorts are too small to estimate rates.

Contaminant Load in Commercial Powders

Zeolite is mined rock, and the ore carries lead, cadmium, arsenic and mercury. European feed authorisation is granted only against defined contaminant limits that unregulated consumer powders need not meet; the same opinion classes the material as a skin and respiratory sensitiser (European Food Safety Authority, 2025).

Magnitude: Direction is a higher contaminant burden the less purified the material; no published survey quantifies contaminant levels across retail zeolite supplements.

Speculative 🟨

Reduced Absorption of Co-Administered Drugs and Nutrients

The pores that adsorb toxins also adsorb medicines and nutrients; laboratory work shows clinoptilolite taking up dietary glucose, lowering blood glucose in mice (Markoska et al., 2023). No study has measured drug adsorption in people.

Fibrous Zeolite Contamination

Erionite, a fibrous zeolite found in some clinoptilolite deposits, is a confirmed human carcinogen causing mesothelioma (cancer of the lung lining) when inhaled (Patel et al., 2022). The risk documented is airborne, not oral.

Aluminium Released by Stomach Acid

Stomach acid can strip aluminium from the crystal framework, a theoretical exposure concern. Human monitoring found no aluminium rise one hour after intake and a fall after four years (Kraljević Pavelić et al., 2022).

Risk-Modifying Factors

  • Genetic polymorphisms: HFE variants (hereditary iron overload) and ATP7B variants (the gene that clears copper from the liver) alter mineral balance, so binding-driven depletion matters more in carriers. ALAD variants change how mobilised lead distributes between blood and tissue.

  • Baseline biomarker levels: Low baseline copper, zinc, ferritin, sodium or calcium narrows the margin before binding produces frank deficiency. High baseline bone lead raises the amount available for transient mobilisation into the bloodstream during remodelling.

  • Sex-based differences: No trial has reported sex-stratified adverse events. Women’s higher rates of low iron stores and the accelerated bone remodelling of the menopausal transition are plausible amplifiers of both mineral depletion and lead mobilisation, but this is unmeasured.

  • Pre-existing health conditions: Chronic kidney disease impairs clearance of mobilised metals and aluminium. Inflammatory bowel disease, diverticular disease (pouches in the colon wall) and constipation raise the burden from an insoluble powder. Immunosuppressive therapy is a documented caution.

  • Age-related considerations: Older adults have larger bone metal stores, more remodelling, thinner mineral reserve and reduced kidney clearance, so both principal risks concentrate at the older end of the target range studied in the osteoporosis trials.

Key Interactions & Contraindications

  • Narrow therapeutic index drugs — small dose changes matter: Levothyroxine, warfarin, digoxin, lithium. Severity: caution. Consequence: adsorption in the gut lowers the absorbed dose enough to lose control of thyroid status, anticoagulation or heart rhythm. Mitigation: doses separated by at least four hours.

  • Antibiotics and anti-seizure medication: Tetracycline and fluoroquinolone antibiotics (doxycycline, minocycline, ciprofloxacin, levofloxacin) and phenobarbital. Severity: caution. Consequence: too little antibiotic in the blood, or loss of seizure control. Mitigation: four-hour dose separation, or suspending zeolite during a short antibiotic course.

  • Over-the-counter medications: Aspirin, ibuprofen, theophylline and acid-suppressing agents (omeprazole, famotidine). Severity: caution. Consequence: reduced analgesic or bronchodilator effect; acid suppression cuts gastric ion exchange and blunts binding. Mitigation: four-hour separation, with the need reassessed.

  • Mineral supplements: Iron, zinc, calcium, magnesium, copper and selenium. Severity: caution. Consequence: additive loss of the cation being supplemented, since the mineral cannot distinguish it from a toxic metal. Mitigation: mineral supplements are taken at the opposite end of the day.

  • Other binders — additive effect: Activated charcoal, bentonite clay, chlorella, modified citrus pectin and prescription bile-acid binders (cholestyramine, colesevelam). Severity: caution. Consequence: compounded depletion of fat-soluble vitamins and minerals, and compounded constipation. Mitigation: binders are not stacked.

  • Chelation therapy — metal-binding drug treatment: Oral or intravenous succimer, DMPS or calcium-disodium EDTA. Severity: caution, specialist supervision. Consequence: unpredictable combined metal movement, since these drugs mobilise stored metal into blood while zeolite acts only in the gut. Mitigation: not combined without specialist supervision.

Populations who should avoid Zeolite:

  • Recipients of solid-organ transplants or anyone on immunosuppressive therapy, given the reported immune-cell shifts
  • Chronic kidney disease at estimated glomerular filtration rate below 30 mL/min/1.73 m² (stage 4–5), where mobilised metals and aluminium clear poorly
  • Pregnancy and lactation, where no human safety data exist and mobilised lead crosses the placenta
  • Active inflammatory bowel disease flare, bowel obstruction or stricture (a narrowed segment of bowel), where an insoluble particulate is contraindicated
  • Diagnosed Wilson disease (inherited copper accumulation) or untreated hereditary haemochromatosis (an inherited disorder causing iron to build up in the body), where copper and iron balance is already disturbed
  • Anyone taking a narrow therapeutic index medication who cannot reliably maintain four-hour dose separation

Risk Mitigation Strategies

  • Four-hour dosing separation from all medication and minerals: Prevents the adsorption-driven loss of drug and nutrient absorption. Taking zeolite mid-morning and mid-afternoon, away from meals and from any prescription or mineral dose, removes most of that interaction risk.

  • Baseline and follow-up mineral panel: Prevents silent depletion of copper, sodium and calcium reported during long-term use. Protocols measure copper, zinc, sodium, calcium and ferritin before starting and at one year, stopping if any falls below the reference range.

  • Blood lead and metals panel before and during use: Catches the transient rise in circulating lead from bone stores. Testing runs at baseline, three months and twelve months; a sustained rather than transient rise is grounds to stop and reassess.

  • Purity documentation before purchase: Prevents contaminant exposure from unpurified ore. A batch certificate of analysis showing lead, cadmium, arsenic and mercury below regulatory limits, plus confirmation the deposit is screened for fibrous zeolite, is the minimum documentation.

  • Low starting dose with slow titration: Limits constipation, bloating and abdominal discomfort. Protocols begin near 1–2 g daily with generous fluid, hold for two weeks, then increase toward the trial range of 3–6 g daily only if tolerated.

  • Time-limited courses rather than indefinite use: Limits cumulative mineral depletion. The bowel and barrier trials ran 8–12 weeks; using defined courses of that length with a break and a repeat mineral panel keeps exposure inside the studied window.

Therapeutic Protocol

  • Standard oral dose: Trials used 1.85–9 g daily of micronised clinoptilolite; the lead-binding study used 2.0–4.0 g, the lipid study 6–9 g, and the bowel study 6 g. Practitioners typically settle near 3 g daily.

  • Conventional approach — purified clinoptilolite tuff: Glock Health, Science and Research markets G-PUR as a purified tuff with defined specifications, positioned for gut-restricted binding, and used in the lead and bowel trials at 2 g two or three times daily.

  • Integrative approach — mechanically activated micropowder: Panaceo International markets PMA-zeolite, where tribomechanical activation enlarges reactive surface area, claimed to raise ion exchange. Used in the chemotherapy, osteoporosis and bowel studies; neither approach has been tested against the other.

  • Best time of day: Away from meals and medication, typically mid-morning and mid-afternoon on an empty stomach. Stomach acid drives the ion exchange, so acid-suppressed conditions and dosing right after a meal both reduce binding.

  • Half-life and residence: There is none in the systemic sense, since the material is not absorbed. What matters is gastrointestinal residence — roughly 24–48 hours of transit — so the binding window is set by transit speed, not by clearance.

  • Split rather than single dosing: Trials divided the daily amount into two or three doses. Splitting maintains binding capacity across the day, matches the two-to-three-times-daily regimens used in the controlled studies, and reduces the particulate load per dose.

  • Genetic polymorphisms: No pharmacogenetic testing informs dosing. Known HFE, ATP7B or ALAD variants argue for the lower end of the range and closer mineral monitoring, because iron, copper and lead handling are already atypical in carriers.

  • Sex-based differences: No dose has been calibrated by sex. Neuropathy reduction reached significance only in men, and the blood alcohol effect was more pronounced in men than women, suggesting smaller effect sizes in women rather than a different dose.

  • Age-related considerations: Older adults produce less stomach acid, so binding efficiency falls while mineral reserve is thinner. The osteoporosis trials dosed this group conventionally; the practical adjustment is closer monitoring rather than a different amount.

  • Baseline biomarker levels: Baseline blood lead, cadmium, copper, zinc, ferritin, sodium and calcium set both the case for use and the safety margin. Negligible metal burden with marginal mineral status argues against starting at all.

  • Pre-existing health conditions: Constipation, diverticular disease or slow transit argue for the low end with added fluid and fibre. Reduced kidney function argues for shorter courses; acid-suppressing therapy argues for reconsidering the intervention entirely.

Discontinuation & Cycling

  • Not a lifelong intervention: Controlled trials ran 8–12 weeks, or through six months of chemotherapy, apart from the five-year osteoporosis study. Continuous indefinite use is unstudied outside that single manufacturer-run trial, and the mineral-depletion signal argues against open-ended intake.

  • No withdrawal effects: The material is not absorbed and acts on no receptor, so there is no physiological dependence or rebound. Stopping produces no recognised withdrawal syndrome in any trial or case report.

  • No taper needed: Because there is no adaptation or dependence, zeolite can be stopped abruptly. The one documented reversal is loss of effect: lipid values returned to baseline within six weeks of stopping in the lipid study.

  • Cycling is reasonable but untested: No trial has compared continuous with intermittent use. Courses matching the 8–12 weeks of the bowel and barrier trials, followed by a break of similar length, allow mineral status to recover.

  • Effects do not persist: What benefit exists appears to depend on the mineral being present in the gut. The lipid reversal after withdrawal indicates a binding effect sustained only during intake, not a durable change.

Sourcing and Quality

  • Clinoptilolite specifically, not “zeolite”: Over ninety natural zeolite species exist and most have never been evaluated for ingestion. The label should name clinoptilolite and state the deposit, since geology drives both contaminant content and fibrous-mineral risk.

  • Contaminant testing on every batch: The ore carries lead, cadmium, arsenic and mercury. A current certificate of analysis showing these below regulatory limits is the minimum; European feed authorisation applies such specifications, while consumer supplements are not required to meet them.

  • Third-party testing and fibrous-mineral screening: Independent verification by a recognised laboratory, plus explicit confirmation that the deposit has been screened for erionite and other fibrous zeolites, is the single most useful quality marker for this material.

  • Particle size and activation are disclosed: Micronised, tribomechanically activated and coarse-ground materials behave differently, and the finest grind produced the largest lipid effect. Products should state particle size and whether the material was mechanically activated.

  • Characterised branded materials: The trials used two defined products — G-PUR purified clinoptilolite tuff from Glock Health, Science and Research, and PMA-zeolite from Panaceo International. Both are manufacturer-characterised and both fund their own trials; generic powders carry no such specification.

Practical Considerations

  • Time to effect: Binding of a co-ingested dose is immediate, within the same meal. Symptom-level changes took four to eight weeks in the bowel and lipid studies; bone and metal-profile changes took months to years.

  • Common pitfalls: Taking the powder with meals, medication or mineral supplements, which wastes binding capacity and causes interactions; buying unspecified “zeolite” rather than clinoptilolite; and continuing indefinitely without ever rechecking mineral status.

  • Expecting whole-body detoxification: The mineral acts only inside the gut. It cannot reach metal already deposited in bone or brain, so framing it as a whole-body metal remover misreads a mechanism confined to the digestive tract.

  • Regulatory status: Authorised in the European Union as a feed additive and marketed there as a medical device for gut applications; sold in the United States as a dietary supplement, with no approved disease claim and documented enforcement action against disease marketing.

  • Cost and accessibility: Inexpensive and widely available without prescription, typically a modest monthly cost. Accessibility is not a constraint; the practical constraint is distinguishing characterised, tested material from unspecified mined powder.

Interaction with Foundational Habits

  • Sleep: No direct interaction. The material is not absorbed, acts on no neurotransmitter system and has no stimulant or sedative property, so timing relative to bedtime is irrelevant. Any indirect effect runs through relief of nocturnal bowel symptoms in those who have them, as reported in the irritable bowel studies.

  • Nutrition: Blunting, and the most consequential interaction. Non-selective ion exchange removes dietary iron, zinc, calcium, copper and magnesium alongside toxic metals, so dosing between meals rather than with them is essential. Adequate fluid intake is required because the material is insoluble and bulk-forming.

  • Exercise: Indirect and neutral for performance. The 12-week endurance trial (Lamprecht et al., 2015) found no change in maximal oxygen uptake or peak performance, and no blunting of training adaptation, with the only measured change in a gut-barrier marker. Dosing away from pre-workout carbohydrate or electrolyte intake avoids adsorbing either.

  • Stress management: Indirect and unmeasured. No study has assessed cortisol or the stress response. The one relevant observation is a favourable trend in a perceived-stress questionnaire alongside symptom relief in the irritable bowel trial (Anderle et al., 2022), which is best read as symptom relief improving mood rather than a direct effect on stress physiology.

Monitoring Protocol & Defining Success

Baseline testing serves two purposes: establishing whether there is a metal burden worth binding, and documenting the mineral reserve that binding could erode. Before starting, a blood heavy-metals panel, serum copper, zinc, ferritin, a comprehensive metabolic panel covering sodium, calcium, kidney and liver measures, and a complete blood count give both. Where the goal is lipid or bowel symptom improvement, a fasting lipid panel and a symptom diary establish the comparison. Ongoing monitoring repeats the mineral and metals panel at three months and again at twelve months, then every six to twelve months during continued use, with lipids rechecked at eight weeks if that is the target. A sustained downward drift in copper, sodium or calcium, or a blood lead level that keeps rising rather than settling, is the signal to stop.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood lead Below 1.0 µg/dL Principal target of binding and principal safety signal Conventional action level is 3.5 µg/dL; functional practitioners target near zero. A transient rise reflects mobilisation from bone
Whole blood cadmium, arsenic, mercury Below laboratory detection limit Establishes whether a binding target exists at all An overnight fast and 72 hours without seafood precede the draw, since fish raises organic arsenic and mercury
Serum copper 80–120 µg/dL Most consistently depleted essential mineral in long-term use Conventional range is wider at 70–140 µg/dL. Best paired with ceruloplasmin (the main copper-carrying blood protein). Fell in osteoporosis patients on multi-year supplementation and normalised on continued use
Serum zinc 90–120 µg/dL Competes for the same exchange sites as toxic cations Conventional lower bound is 70 µg/dL. Morning fasting draw; levels fall during acute inflammation, so it is read alongside C-reactive protein, a general inflammation marker
Serum sodium 138–142 mmol/L Dropped below reference during long-term supplementation Conventional range extends to 135 mmol/L; the functional target is narrower. Not fasting-dependent
Serum calcium, albumin-corrected 9.2–10.0 mg/dL Dropped below reference in the osteoporosis cohort Requires albumin correction, or an ionised calcium instead; conventional lower bound is 8.5 mg/dL
Ferritin 50–150 ng/mL Detects iron depletion from non-selective binding Conventional laboratories call anything above 15–30 ng/mL normal, far below the functional floor. Ferritin reflects stored iron and rises with inflammation, so it is best paired with C-reactive protein and with transferrin saturation, the share of the iron-carrying protein actually loaded with iron
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Clearance of mobilised metals and aluminium depends on it eGFR is estimated glomerular filtration rate, a measure of kidney filtering capacity. Conventional threshold for concern is 60
ALT and AST Below 25 U/L (men), below 20 U/L (women) Screens for liver injury attributed to supplements ALT and AST are alanine and aspartate aminotransferase, liver enzymes released when liver cells are damaged. Conventional upper limits run to 40 U/L
Complete blood count Haemoglobin 13.5–15.0 g/dL (women), 14.5–16.0 g/dL (men); white cells 4.0–7.0 ×10⁹/L; platelets 175–250 ×10⁹/L Detects anaemia from mineral depletion and the immune-cell shifts reported in one study A complete blood count measures red cells, white cells and platelets. Conventional ranges are looser: haemoglobin from 12.0 g/dL, white cells to 11.0 ×10⁹/L, platelets 150–400 ×10⁹/L. Non-fasting
Fasting lipid panel Low-density lipoprotein cholesterol below 100 mg/dL, triglycerides below 100 mg/dL The one quantified efficacy signal outside metal binding Twelve-hour fast; the conventional triglyceride limit is the looser 150 mg/dL. Rechecked at eight weeks, the interval at which the lipid study saw its full effect
Stool zonulin No established target; track change from the individual’s own baseline The marker that moved in the endurance trial Not validated against clinical outcomes, so useful only as a within-person trend, not as a treatment goal

Qualitative markers worth tracking alongside laboratory values:

  • Stool frequency and consistency, scored on a standard stool form scale, since bowel change is the most consistently reported effect
  • Abdominal pain and bloating days per week, the measures that improved in the bowel studies
  • Constipation, the commonest complaint with any insoluble binder and the usual reason for stopping
  • Energy levels and exercise tolerance, which detect developing iron or mineral depletion before laboratory values fall below range
  • Cognitive clarity and mood, tracked because self-reported wellbeing is the outcome most vulnerable to expectation effects with this intervention

Emerging Research

  • Blood alcohol adsorption trial: NCT07332429, a quadruple-blinded, placebo-controlled trial of 228 healthy adults in Brazil, gives effervescent clinoptilolite before or after a standardised alcohol dose. It is the first adequately powered test of the gastric adsorption claim; the 12-person pilot it follows was uncontrolled.

  • Crohn’s disease and gut barrier: NCT04370535 randomised 40 subjects, healthy and Crohn’s, to PMA-zeolite or cellulose placebo, with faecal zonulin as its primary endpoint. Its registry status is unknown and no results have been posted, which itself weakens the case.

  • Cholesterol absorption kinetics: NCT03090542, a completed 22-person study measuring fractional cholesterol absorption over six days, would establish whether the 20–25% lipid reduction reported by Cutovic et al., 2017 reflects bile-acid binding. No results have been published.

  • Long-term bone outcomes: NCT05178719 carried 81 patients from the original osteoporosis cohort (Kraljević Pavelić et al., 2022) through four more years on PMA-zeolite, single-arm. Without a placebo arm it cannot settle whether fracture reduction without bone mineral density gain is real.

  • Toxicology supporting food-ingredient status: A 90-day repeated-dose rat study with a full genotoxicity battery found no adverse or mutagenic effects and supports a generally-recognised-as-safe determination (Smith et al., 2026). Animal toxicology, however, does not address the human mineral-depletion signal.

  • Research that could weaken the case: The one blinded bowel trial missed its primary endpoint (Anderle et al., 2022), and independent replication of the manufacturer-funded chemotherapy and osteoporosis results is absent. Adequately powered trials by groups without commercial ties are the decisive missing evidence.

Conclusion

Zeolite is a mined volcanic mineral, taken as a powder, that works entirely inside the digestive tract. It is not absorbed, so whatever it does follows from what it binds and carries out in stool. The strongest single finding is that taking it alongside an ingested dose of lead sharply reduces how much of that lead enters the bloodstream. Smaller and weaker studies point to improved blood fats, fewer diarrhoea days, better tolerance of one chemotherapy drug, and fewer bone fractures.

Against this sits a consistent pattern in the evidence base itself: almost every human study was funded, co-authored or run by a company selling the product, and the two signals that cut the other way — the disappointing result of the only properly controlled bowel study, and the loss of essential minerals picked up by the makers’ own blood monitoring — came from inside that same circle. The binding is not selective, so useful minerals leave with the harmful ones, and metal stored in bone can move into the blood before it leaves the body.

For adults willing to test and monitor, this is a cheap, low-burden intervention whose case rests on one well-executed trial and a scatter of uncontrolled reports. The size of any durable health effect is genuinely uncertain, and the product’s purity varies more than its biology does.

Top - Benefits - Risks - Protocol